Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers

Journal of Clinical Pharmacology

Volumn 48, Issue 10, 2008, Pages 1171-1178

  Huttner S ^a   Graefe Mody, E U ^a   Withopf, B ^a   Ring, A ^b   Dugi, K A ^b  

^a B Ingelheim Pharma GmbH/Co KG   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

BI 1356; Dipeptidyl peptidase 4 inhibitor; Pharmacodynamics; Pharmacokinetics; Type 2 diabetes

Indexed keywords

8 (3 AMINOPIPERIDIN 1 YL) 7 BUT 2 YNYL 3 METHYL 1 (4 METHYLQUINAZOLIN 2 YLMETHYL) 3,7 DIHYDROPURINE 2,6 DIONE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ONDERO; PLACEBO; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG DOSAGE FORM COMPARISON; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; ELECTROCARDIOGRAM; FLU LIKE SYNDROME; HEADACHE; HEART CONDUCTION; HEART RHYTHM; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; MALE; NAUSEA; NORMAL HUMAN; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; URINARY EXCRETION; VOLUNTEER; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANTIGENS, CD26; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PURINES; QUINAZOLINES; YOUNG ADULT;

EID: 51849103389     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008323753     Document Type: Article

References (34)

1. Wild S., Roglic G., Green A., et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004 ; 27: 1047-1053.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2005 ; 28: S37 - S42.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 ; 352: 837-853.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 ; 329: 977-986.
5. Inzucchi SE Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002 ; 287: 360-372.
6. Mentlein R., Gallwitz B., Schmidt WE Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993 ; 214: 829-835.
7. Deacon CF, Johnsen AH, Holst JJ Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995 ; 80: 952-957.
8. Lankas GR, Leiting B., Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 2005 ; 54: 2988-2994.
9. Elliott RM, Morgan LM, Tredger JA, et al. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute postprandial and 24-h secretion patterns. J Endocrinol. 1993 ; 138: 159-166.
10. Nauck MA, Bartels E., Orskov C., et al. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab. 1993 ; 76: 912-917.
11. Nauck MA, Sauerwald A., Ritzel R., et al. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care. 1998 ; 21: 1925-1931.
12. Nauck MA, Kleine N., Orskov C., et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993 ; 36: 741-744.
13. Kreymann B., Williams G., Ghatei MA, Bloom SR Glucagonlike peptide-1 7-36: a physiological incretin in man. Lancet. 1987 ; 2: 1300-1304.
14. Deacon CF Therapeutic strategies based on glucagon like peptide 1. Diabetes. 2004 ; 53: 2181-2189.
15. Ahren B., Gomis R., Standl E., et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformintreated patients with type 2 diabetes. Diabetes Care. 2004 ; 27: 2874-2880.
16. Näslund E., Bogefors J., Skogar S., et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol. 1999 ; 277: R910 - R916.
17. Delgado-Aros S., Kim DY, Burton DD, et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol. 2002 ; 282: G424 - G431.
18. Zander M., Madsbad S., Madsen JL, Holst JJ Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002 ; 359: 824-830.
19. Holst JJ Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev. 2002 ; 18: 430-441.
20. Pospisilik JA, Martin J., Doty T., et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 2003 ; 52: 741-750.
21. Reimer MK, Holst JJ, Ahren B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol. 2002 ; 146: 717-727.
22. Drucker DJ Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003 ; 26: 2929-2940.
23. Buse J., Henry R., Han J., et al. Effect of exenatide (exendin-4) on glycemic control and safety over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes. 2004 ; 52 (Suppl 2). A82.
24. Calara F., Taylor K., Han J., et al. Effect of injection site on relative bioavailability of exenatide (synthetic exendin-4). Diabetes. 2004 ; 52 (Suppl 2). A120.
25. Drucker DJ, Nauck MA The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-IV inhibitors in type 2 diabetes. Lancet. 2006 ; 368: 1696-1705.
26. Idris I., Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diabetes Obes Metab. 2007 ; 9: 153-165.
27. Lankas G., Leiting B., Roy RS, et al. Dipeptidyl peptidase-IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidase 8 and 9. Diabetes. 2004 ; 54: 2988-2994.
28. Eckhardt M., Langkopf E., Mark M., et al. 8-(3-(R)-aminopiperidin-1-yl)- 7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2, 6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem. 2007 ; 50 (26). 6450-6453.
29. Thomas L., Eckhardt M., Langkopf E., et al. BI 1356 (proposed trade name ONDERO), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other DPP-4 inhibitors. J Pharmacol Exp Ther. 2008 ; 325 (1). 175-182.
30. Meisel S., Shamiss A., Rosenthal T. Clinical pharmacokinetics of ramipril. Clin Pharmacokinet. 1994 ; 26 (1). 7-15.
31. Dittberner S., Duval V., Staab A., Troconiz I., Graefe-Mody U., Jaehde U. Determination of the absolute bioavailability of BI 1356, a substance with nonlinear pharmacokinetics, using a population pharmacokinetic modelling approach. Poster presented at: 16th Annual Meeting of the Population Approach Group in Europe ; June 2007 ; København, Denmark [abstract 1110]. Available at: www.page-meeting.org/?abstract=1110.
32. American Diabetes Association. Nephropathy in diabetes. Diabetes Care. 2004 ; 27: S79 - S83.
33. Chadban SJ, Briganti EM, Kerr PG, et al. Prevalence of kidney damage in Australian adults: the AusDiab Kidney Study. J Am Soc Nephrol. 2003 ; 14 (7 Suppl 2). S131 - S138.
34. Herman GA, Stevens C., Van Dyck K., et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from 2 randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005 ; 78 (6). 675-688.